"thyroiditis: most commonly associated with anti–PD-1 therapy, or combined anti–PD-1 and anti–CTLA-4 therapy 6"
"thyroiditis: most commonly associated with anti–PD-1 therapy, or combined anti–PD-1 and anti–CTLA-4 therapy 6"
"thyroiditis: most commonly associated with anti–PD-1 therapy, or combined anti–PD-1 and anti–CTLA-4 therapy 6"
Expected headings
"Complications"
"programmed cell death protein 1 (PD-1): nivolumab, pembrolizumab, cemiplimab, dostarlimab, tislelizumab, toripalimab, retifanlimab"
"laboratory values may represent a cholestatic, hepatocellular or mixed picture 6"
"imaging findings may include a mild hepatomegaly, periportal oedema, and lymphadenopathy; focal hepatic abnormalities can also rarely occur 6"